RxDoctor Payments Data

Giri Mundluru, MD

Interventional Cardiology · Fort Worth, TXNPI 1912904491

Payments from drug & device makers

$49,046in general payments, 2019–2025

Across 560 payments — averaging $87.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cleerly, Inc.$18K
  • Medtronic$12K
  • Penumbra, Inc.$5K
  • Abbott$3K
  • Abiomed$3K
  • Boston Scientific$1K
  • plus $7K from 36 others
$30in research payments, 2019–2025

Across 1 payment — averaging $29.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$30

What the payments were for

  • Consulting fees$5002%
  • Travel & lodging$12,10839%
  • Food & beverage$18,47059%
  • Education$780%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,046 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$319,078
Medicare patients
713
Services billed
2,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban254$264,343
EntrestoSacubitril/Valsartan77$94,207
XareltoRivaroxaban46$47,386
Ranolazine ErRanolazine39$5,161
ClopidogrelClopidogrel Bisulfate221$2,277
Atorvastatin Calcium251$2,272
Metoprolol Succinate114$2,027
Carvedilol279$1,939
Rosuvastatin Calcium143$1,672
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid165$1,566
Losartan Potassium136$1,086
Metoprolol Tartrate138$933
Ezetimibe33$846
Amiodarone Hcl18$773
Amlodipine Besylate138$761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$137$264,343254 claims
NovartisEntresto$1,245$94,20777 claims
Johnson & JohnsonXarelto$473$47,38646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →